Abilita Bio Overview

  • Founded
  • 2014

Founded
  • Status
  • Private

  • Latest Deal Type
  • Grant

  • Investors
  • 3

Abilita Bio General Information

Description

Owner and operator of an innovation-driven biotechnology company intended to develop drugs targeting membrane proteins. The company's services mainly focus on discovering and developing therapeutic drugs and technologies to enable discovery and development of drugs targeting membrane proteins including G protein-coupled receptors (GPCRs) and ion channels through the application of its enabled membrane proteins technology platform, enabling clients to have access to tool receptors for antibody discovery and a technical service through the generation of enabled membrane proteins.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Primary Office
  • 3210 Merryfield Row
  • San Diego, CA 92121
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Abilita Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 20-Sep-2016 Completed Startup
3. Grant 01-Jan-2016 00000 Completed Startup
2. Accelerator/Incubator 01-Jan-2015 Completed Startup
1. Angel (individual) 01-Jan-2015 Completed Startup
To view Abilita Bio’s complete valuation and funding history, request access »

Abilita Bio Patents

Abilita Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017259821-A1 Methods and platform for preparing multispanning membrane proteins Pending 04-May-2016 0000000000
EP-3452516-A1 Methods and platform for preparing multispanning membrane proteins Pending 04-May-2016 0000000000
EP-3452516-A4 Methods and platform for preparing multispanning membrane proteins Pending 04-May-2016 0000000000
JP-2019527065-A Methods and platforms for preparing multiple transmembrane proteins Pending 04-May-2016 0000000000
US-10845367-B2 Modified multispanning membrane polypeptides and methods of use thereof to screen therapeutic agents Active 04-May-2016 G01N33/577 00
To view Abilita Bio’s complete patent history, request access »

Abilita Bio Executive Team (4)

Name Title Board Seat Contact Info
Mauro Mileni Ph.D Founder & Chief Executive Officer
James Schmidt Chief Financial Officer
Rosario Billetta Chief Technology Officer
You’re viewing 3 of 4 executive team members. Get the full list »

Abilita Bio Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Cancer Institute Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Johnson & Johnson Innovation - JLABS Accelerator/Incubator 000 0000 000000 0
To view Abilita Bio’s complete investors history, request access »